Alkahest, a company that analyzes blood proteins to develop therapies that address neurological disorders including Alzheimer’s disease, is set to be acquired by partner Grifols in a $146 million deal.
Grifols (NASDAQ: GRFS) announced Tuesday that it is acquiring the shares of privately held Alkahest that it does not already own. Barcelona-based Grifols says the deal will help it discover new therapies for age-related diseases.
Alkahest develops its therapeutic candidates by analyzing the proteome, the range of proteins produced by cells, tissues and organs. The San Carlos, CA-based biotech’s research on the proteome of plasma identified chronokines, proteins that the... Read more »
UNDERWRITERS AND PARTNERS
Author: Frank Vinluan
Date : 2020-09-08T17:41:46.000Z